Immix Biopharma’s (IMMX) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Immix Biopharma (NASDAQ:IMMX) in a research note published on Monday morning, Benzinga reports. They currently have a $7.00 price objective on the stock. HC Wainwright also issued estimates for Immix Biopharma’s Q3 2024 earnings at ($0.16) EPS, Q4 2024 earnings at ($0.17) EPS, FY2024 earnings at ($0.67) EPS, Q1 2025 earnings at ($0.13) EPS, Q2 2025 earnings at ($0.14) EPS, Q3 2025 earnings at ($0.13) EPS, Q4 2025 earnings at ($0.12) EPS and FY2025 earnings at ($0.52) EPS.

Immix Biopharma Stock Performance

Shares of IMMX opened at $2.28 on Monday. Immix Biopharma has a 1 year low of $1.75 and a 1 year high of $7.75. The firm has a fifty day moving average of $2.10 and a 200-day moving average of $2.47. The company has a market cap of $60.22 million, a price-to-earnings ratio of -2.45 and a beta of 0.17.

Immix Biopharma (NASDAQ:IMMX) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.06. Analysts predict that Immix Biopharma will post -0.88 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. OLD National Bancorp IN acquired a new stake in Immix Biopharma in the fourth quarter worth about $69,000. Jump Financial LLC acquired a new stake in shares of Immix Biopharma in the 4th quarter worth approximately $128,000. Tritonpoint Wealth LLC bought a new position in shares of Immix Biopharma in the first quarter valued at approximately $75,000. Invst LLC acquired a new position in shares of Immix Biopharma during the second quarter valued at approximately $57,000. Finally, Tocqueville Asset Management L.P. raised its holdings in Immix Biopharma by 89.0% during the first quarter. Tocqueville Asset Management L.P. now owns 37,800 shares of the company’s stock worth $116,000 after purchasing an additional 17,800 shares in the last quarter. Institutional investors and hedge funds own 11.26% of the company’s stock.

About Immix Biopharma

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.